Condensed Statements of Stockholders’ Equity (Unaudited) (USD $) In Thousands, except Share data	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Translation Adjustment [Member]	Total
Balances at July 1, 2012 at Jun. 30, 2012	$ 100,394	$ 668	$ (1,397)	$ (69,900)	$ 29,516	$ 59,281
Balances at July 1, 2012 (in Shares) at Jun. 30, 2012	182,350,316		(1,816,178)			182,350,316
Exchange differences on translation of foreign operations					1,537	1,537
Net loss				(2,198)		(2,198)
Total Comprehensive income						(661)
New shares issued on exercise of options	410	(410)
New shares issued on exercise of options (in Shares)	413,335
New shares issued on vesting of options on merger	1,118	(1,118)
New shares issued on vesting of options on merger (in Shares)	4,639,104
Acquisition of Nabi Biopharmaceuticals	(98,521)	233,367	(115,651)			19,195
Acquisition of Nabi Biopharmaceuticals (in Shares)	(153,398,048)		(4,051,183)
Restricted stock units, net	21	(21)
Restricted stock units, net (in Shares)	214,983
Share-based compensation		2,289				2,289
Balances at March 31, 2013 at Mar. 31, 2013	$ 3,422	$ 234,775	$ (117,048)	$ (72,098)	$ 31,053	$ 80,104
Balances at March 31, 2013 (in Shares) at Mar. 31, 2013	34,219,690		(5,867,361)			34,219,690